Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Nguyen BB, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre J, de Gislain C, Bensadoun JR, Clavel M. Mornex F, et al. Among authors: clavel m. Cancer Radiother. 2003 Feb;7(1):1-8. doi: 10.1016/s1278-3218(02)00284-6. Cancer Radiother. 2003. PMID: 12648711 Clinical Trial. French.
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M. Mornex F, et al. Among authors: clavel m. Melanoma Res. 2003 Feb;13(1):97-103. doi: 10.1097/00008390-200302000-00016. Melanoma Res. 2003. PMID: 12569292 Clinical Trial.
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Fumoleau P, Chauvin F, Namer M, Bugat R, Tubiana-Hulin M, Guastalla JP, Delozier T, Kerbrat P, Devaux Y, Bonneterre J, Filleul A, Clavel M. Fumoleau P, et al. Among authors: clavel m. J Clin Oncol. 2001 Feb 1;19(3):612-20. doi: 10.1200/JCO.2001.19.3.612. J Clin Oncol. 2001. PMID: 11157010 Clinical Trial.
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M. Catimel G, et al. Among authors: clavel m. Ann Oncol. 1995 Feb;6(2):133-40. doi: 10.1093/oxfordjournals.annonc.a059108. Ann Oncol. 1995. PMID: 7786821 Free article. Clinical Trial.
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, et al. Clavel M, et al. Ann Oncol. 1994 Jul;5(6):521-6. doi: 10.1093/oxfordjournals.annonc.a058906. Ann Oncol. 1994. PMID: 7522527 Free article. Clinical Trial.
529 results